On August 25, 2026 Genmab A/S (Nasdaq: GMAB) reported that members of its Executive Committee will participate in fireside chats at the following investor conferences in September 2026:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Wells Fargo 21st Annual Healthcare Conference in Boston on September 9, 2026, 3:00 PM EDT
24th Annual Morgan Stanley Global Healthcare Conference in New York City on September 15, 2026, 8:30 AM EDT
Bank of America Global Healthcare Conference in London on September 22, 2026, 10:55 AM BST

The live and archived webcast of the presentations will be available on Genmab’s website at View Source

(Press release, Genmab, AUG 25, 2026, View Source [SID1234670317])

On August 25, 2026 Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, reported that Jim Davis, Chairman, CEO and President, will speak on the company’s strategy, performance and the latest market developments and trends during the Baird 2026 Global Healthcare Conference in New York City on Tuesday, September 15, 2026, at 10:50 a.m. Eastern Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The fireside chat and Q&A session will be webcast live during the conference on the company’s investor relations page, which can be accessed at ir.QuestDiagnostics.com. In addition, the archived webcast will be available within 24 hours after the conclusion of the live event and will remain available until October 13, 2026.

(Press release, Quest Diagnostics, AUG 25, 2026, View Source [SID1234670316])

On August 25, 2026 Oxcia AB reported interim results for the second quarter 2026. Oxcia’s financial reports are only available in Swedish. They can be found Finansiella rapporter – Oxcia and Pressmeddelanden Archives – Oxcia.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

For more information contact:

Ulrika Warpman Berglund, CEO, Oxcia AB (publ)

Telephone: +46 (0) 73 270 9605
[email protected]

(Press release, Oxcia, AUG 25, 2026, View Source;utm_medium=rss&utm_campaign=oxcia-ab-publ-publishes-interim-report-for-the-second-quarter-2026 [SID1234670315])

On August 25, 2026 Circio Holding ASA (OSE: CRNA), a biotechnology company developing novel circular RNA expression technology for gene and cell therapy, reported it will host a live webcast from its R&D headquarter in Stockholm, Sweden, at 10:00am CEST on Tuesday 1 September 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In the webcast, CEO Dr. Erik D Wiklund and CFO Dr. Lubor Gaal will provide a corporate update including a summary of first half 2026 financials and an overview of Circio´s extensive business development activities. CTO Dr. Thomas B Hansen will present the most recent circVec pre-clinical results, including promising new in vivo data generated in heart and CNS gene therapy, as well as advances on the in vivo CAR-T program.

The first half year 2026 report will be published on 31 August 2026, and further information and presentation materials will be published ahead of the webcast on 1 September 2026.

The webcast will be held in English. Questions can be submitted in advance by email to Erik D Wiklund: [email protected] or directly in the live webcast.

Time: 10:00 CEST on Tuesday 1 September 2026

Click here to access Teams webcast
Meeting ID: 343 877 779 042 528
Passcode: MD3Pv2nP

A recording of the webcast will be made available on the Circio webpage and the presentation materials are attached hereto.

(Press release, Circio, AUG 25, 2026, View Source [SID1234670314])

On August 25, 2026 AstraZeneca PLC (the Company) reported that, on 24 August 2026, its wholly owned subsidiary AstraZeneca Finance LLC, successfully priced four tranches of Eurobonds totalling €2.55 billion (the Offering). The Offering is expected to close on 1 September 2026, subject to customary closing conditions. This issuance is aligned with the Company’s long term funding strategy.

The Offering consisted of the following notes, issued by AstraZeneca Finance LLC and fully and unconditionally guaranteed by the Company:

● €700 million of fixed rate notes with a coupon of 3.402% maturing on 1 March 2030;
● €600 million of fixed rate notes with a coupon of 3.652% maturing on 1 September 2032;
● €500 million of fixed rate notes with a coupon of 3.923% maturing on 1 September 2035; and
● €750 million of fixed rate notes with a coupon of 4.169% maturing on 1 September 2038 (together, the Notes).

The Company expects to use the net proceeds of the offering for general corporate purposes.

Barclays Bank PLC, Goldman Sachs International and Morgan Stanley acted as joint book-running managers on the transaction.

The Notes will be issued under the Euro Medium Term Note (EMTN) programme of the Company and AstraZeneca Finance LLC and admitted to listing on the UK Financial Conduct Authority’s Official List and to trading on the London Stock Exchange’s Main Market.

The Notes have not been registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption from registration.

This announcement shall not constitute an offer to sell or the solicitation of an offer to buy the Notes described herein, nor shall there be any sale of these Notes in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(Press release, AstraZeneca, AUG 25, 2026, View Source [SID1234670313])